Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Jorma Isola

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Physiology

Chemicals & Drugs

Phenomena

Nucleic Acid Hybridization

Genes & Molecular Sequences

erbB-2 Genes

Anatomy

Concepts & Ideas

Gene Dosage

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Côme Christophe; Laine Anni; Chanrion Maïa; Edgren Henrik; Mattila Elina; Liu Xiaoling; Jonkers Jos; Ivaska Johanna; Isola Jorma; Darbon Jean-Marie; Kallioniemi Olli; Thézenas Simon; Westermarck Jukka
CIP2A is associated with human breast cancer aggressivity.
Maurer Matthew; Su Tao; Saal Lao H; Koujak Susan; Hopkins Benjamin D; Barkley Christina R; Wu Jiaping; Nandula Subhadra; Dutta Bhaskar; Xie Yuli; Chin Y Rebecca; Kim Da-In; Ferris Jennifer S; Gruvberger-Saal Sofia K; Laakso Mervi; Wang Xiaomei; Memeo Lorenzo; Rojtman Albert; Matos Tulio; Yu Jennifer S; Cordon-Cardo Carlos; Isola Jorma; Terry Mary Beth; Toker Alex; Mills Gordon B; Zhao Jean J; Murty Vundavalli V V S; Hibshoosh Hanina; Parsons Ramon
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Laurila Marita; Tammela Teuvo L J; Auvinen Anssi; Isola Jorma; Visakorpi Tapio; Luukkaala Tiina; Määttänen Liisa; Ruutu Mirja; Ala-Opas Martti; Mildh Markus; Martikainen Paula
Biological aggressiveness of prostate cancer in the Finnish screening trial.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jorma Isola (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Côme Christophe; Laine Anni; Chanrion Maïa; Edgren Henrik; Mattila Elina; Liu Xiaoling; Jonkers Jos; Ivaska Johanna; Isola Jorma; Darbon Jean-Marie; Kallioniemi Olli; Thézenas Simon; Westermarck Jukka
CIP2A is associated with human breast cancer aggressivity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5092-100.
2009: Maurer Matthew; Su Tao; Saal Lao H; Koujak Susan; Hopkins Benjamin D; Barkley Christina R; Wu Jiaping; Nandula Subhadra; Dutta Bhaskar; Xie Yuli; Chin Y Rebecca; Kim Da-In; Ferris Jennifer S; Gruvberger-Saal Sofia K; Laakso Mervi; Wang Xiaomei; Memeo Lorenzo; Rojtman Albert; Matos Tulio; Yu Jennifer S; Cordon-Cardo Carlos; Isola Jorma; Terry Mary Beth; Toker Alex; Mills Gordon B; Zhao Jean J; Murty Vundavalli V V S; Hibshoosh Hanina; Parsons Ramon
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Cancer research 2009;69(15):6299-306.
2009: Laurila Marita; Tammela Teuvo L J; Auvinen Anssi; Isola Jorma; Visakorpi Tapio; Luukkaala Tiina; Määttänen Liisa; Ruutu Mirja; Ala-Opas Martti; Mildh Markus; Martikainen Paula
Biological aggressiveness of prostate cancer in the Finnish screening trial.
International journal of cancer. Journal international du cancer 2009;124(3):547-52.
2009: Köninki Katri; Tanner Minna; Auvinen Anssi; Isola Jorma
HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.
Breast cancer research : BCR 2009;11(3):R37.
2009: Korja Miikka; Jokilammi Anne; Salmi Toivo T; Kalimo Hannu; Pelliniemi Tarja-Terttu; Isola Jorma; Rantala Immo; Haapasalo Hannu; Finne Jukka
Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma.
BMC cancer 2009;9():57.
2008: Dihge Looket; Bendahl Pär-Ola; Grabau Dorthe; Isola Jorma; Lövgren Kristina; Rydén Lisa; Fernö Mårten
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Breast cancer research and treatment 2008;109(2):255-62.
2008: Barok Márk; Balázs Margit; Nagy Péter; Rákosy Zsuzsa; Treszl Andrea; Tóth Eniko; Juhász István; Park John W; Isola Jorma; Vereb György; Szöllosi János
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
Cancer letters 2008;260(1-2):198-208.
2008: Laitinen Sari; Martikainen Paula M; Tolonen Teemu; Isola Jorma; Tammela Teuvo L J; Visakorpi Tapio
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
International journal of cancer. Journal international du cancer 2008;122(3):595-602.
2008: Saal Lao H; Gruvberger-Saal Sofia K; Persson Camilla; Lövgren Kristina; Jumppanen Mervi; Staaf Johan; Jönsson Göran; Pires Maira M; Maurer Matthew; Holm Karolina; Koujak Susan; Subramaniyam Shivakumar; Vallon-Christersson Johan; Olsson Håkan; Su Tao; Memeo Lorenzo; Ludwig Thomas; Ethier Stephen P; Krogh Morten; Szabolcs Matthias; Murty Vundavalli V V S; Isola Jorma; Hibshoosh Hanina; Parsons Ramon; Borg Ake
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
Nature genetics 2008;40(1):102-7.
2008: Parkkila Seppo; Pan Pei-Wen; Ward Aoife; Gibadulinova Adriana; Oveckova Ingrid; Pastorekova Silvia; Pastorek Jaromir; Martinez Alejandra Rodriguez; Helin Henrik O; Isola Jorma
The calcium-binding protein S100P in normal and malignant human tissues.
BMC clinical pathology 2008;8():2.
2007: Pályi-Krekk Zsuzsanna; Barok Márk; Isola Jorma; Tammi Markku; Szöllosi János; Nagy Peter
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
European journal of cancer (Oxford, England : 1990) 2007;43(16):2423-33.
2007: Aqeilan Rami I; Donati Valentina; Gaudio Eugenio; Nicoloso Milena S; Sundvall Maria; Korhonen Anna; Lundin Johan; Isola Jorma; Sudol Marius; Joensuu Heikki; Croce Carlo M; Elenius Klaus
Association of Wwox with ErbB4 in breast cancer.
Cancer research 2007;67(19):9330-6.
2007: Barok Márk; Isola Jorma; Pályi-Krekk Zsuzsanna; Nagy Péter; Juhász István; Vereb György; Kauraniemi Päivikki; Kapanen Anita; Tanner Minna; Vereb György; Szöllösi János
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Molecular cancer therapeutics 2007;6(7):2065-72.
2007: Laukkarinen Johanna M; Sand Juhani A; Chow Pierce; Juuti Hanne; Kellomäki Minna; Kärkkäinen Päivi; Isola Jorma; Yu Sidney; Somanesan Satchithanantham; Kee Irene; Song In Chin; Ng Teck Hin; Nordback Isto H
A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: an 18-month follow-up in a large animal model.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2007;11(6):750-7.
2007: Saal Lao H; Johansson Peter; Holm Karolina; Gruvberger-Saal Sofia K; She Qing-Bai; Maurer Matthew; Koujak Susan; Ferrando Adolfo A; Malmström Per; Memeo Lorenzo; Isola Jorma; Bendahl Pär-Ola; Rosen Neal; Hibshoosh Hanina; Ringnér Markus; Borg Ake; Parsons Ramon
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7564-9.
2007: Sand Juhani; Tani Taneli; Laukkarinen Johanna; Välikoski Anu; Isola Jorma; Nordback Isto
Ultra thin needle histology may have impact in diagnosing chronic pancreatitis.
Scandinavian journal of gastroenterology 2007;42(4):508-12.
2007: Gruvberger-Saal Sofia K; Bendahl Pär-Ola; Saal Lao H; Laakso Mervi; Hegardt Cecilia; Edén Patrik; Peterson Carsten; Malmström Per; Isola Jorma; Borg Ake; Fernö Mårten
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):1987-94.
2007: Rennstam Karin; Jönsson Göran; Tanner Minna; Bendahl Pär-Ola; Staaf Johan; Kapanen Anita I; Karhu Ritva; Baldetorp Bo; Borg Ake; Isola Jorma
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.
Cancer genetics and cytogenetics 2007;172(2):95-106.
2007: Jumppanen Mervi; Gruvberger-Saal Sofia; Kauraniemi Päivikki; Tanner Minna; Bendahl Pär-Ola; Lundin Mikael; Krogh Morten; Kataja Pasi; Borg Ake; Fernö Mårten; Isola Jorma
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Breast cancer research : BCR 2007;9(1):R16.
2006: Laakso M; Tanner M; Isola J
Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
The Journal of pathology 2006;210(1):3-9.
2006: Järvelä Sally; Helin H; Haapasalo J; Järvelä Timo; Junttila T T; Elenius K; Tanner M; Haapasalo H; Isola J
Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival.
Neuropathology and applied neurobiology 2006;32(4):441-50.
2006: Laakso Mervi; Tanner Minna; Nilsson Jonas; Wiklund Tom; Erikstein Björn; Kellokumpu-Lehtinen Pirkko; Malmström Per; Wilking Nils; Bergh Jonas; Isola Jorma
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4185-91.
2006: Tanner Minna; Isola Jorma; Wiklund Tom; Erikstein Björn; Kellokumpu-Lehtinen Pirkko; Malmström Per; Wilking Nils; Nilsson Jonas; Bergh Jonas
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2428-36.
2006: Zsebik Barbara; Citri Ami; Isola Jorma; Yarden Yosef; Szöllosi János; Vereb György
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Immunology letters 2006;104(1-2):146-55.
2006: Helin Henrik O; Lundin Mikael E; Laakso Mervi; Lundin Johan; Helin Heikki J; Isola Jorma
Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry.
The Journal of urology 2006;175(2):495-9.
2006: Määttä Jorma A; Sundvall Maria; Junttila Teemu T; Peri Liisa; Laine V Jukka O; Isola Jorma; Egeblad Mikala; Elenius Klaus
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.
Molecular biology of the cell 2006;17(1):67-79.
2005: Korja Miikka; Finne Jukka; Salmi Toivo T; Kalimo Hannu; Karikoski Riitta; Tanner Minna; Isola Jorma; Haapasalo Hannu
Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(12):1599-605.
2005: Laakso Mervi; Loman Niklas; Borg Ake; Isola Jorma
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(10):1321-8.
2005: Mocanu Maria-Magdalena; Fazekas Zsolt; Petrás Miklós; Nagy Péter; Sebestyén Zsolt; Isola Jorma; Tímár József; Park John W; Vereb György; Szöllosi János
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
Cancer letters 2005;227(2):201-12.
2005: Korja M; Finne J; Salmi T T; Haapasalo H; Tanner M; Isola J
No GIST-type c-kit gain of function mutations in neuroblastic tumours.
Journal of clinical pathology 2005;58(7):762-5.
2005: Haapasalo J; Mennander A; Helen P; Haapasalo H; Isola J
Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas.
Journal of clinical pathology 2005;58(3):263-8.
2005: Junttila Teemu T; Sundvall Maria; Lundin Mikael; Lundin Johan; Tanner Minna; Härkönen Pirkko; Joensuu Heikki; Isola Jorma; Elenius Klaus
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.
Cancer research 2005;65(4):1384-93.
2005: Tanner M; Hollmén M; Junttila T T; Kapanen A I; Tommola S; Soini Y; Helin H; Salo J; Joensuu H; Sihvo E; Elenius K; Isola J
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(2):273-8.
2005: Nagy Peter; Friedländer Elza; Tanner Minna; Kapanen Anita I; Carraway Kermit L; Isola Jorma; Jovin Thomas M
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Cancer research 2005;65(2):473-82.
2004: Tanner Minna; Kapanen Anita I; Junttila Teemu; Raheem Olayinka; Grenman Seija; Elo Jussi; Elenius Klaus; Isola Jorma
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer.
Molecular cancer therapeutics 2004;3(12):1585-92.
2004: Di Leo A; Chan S; Paesmans M; Friedrichs K; Pinter T; Cocquyt V; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Von Minckwitz G; Leroy J Y; Durbecq V; Isola J; Aapro M; Piccart M J; Larsimont D
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Breast cancer research and treatment 2004;86(3):197-206.
2004: Isola Jorma; Tanner Minna; Forsyth Amanda; Cooke Timothy G; Watters Amanda D; Bartlett John M S
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4793-8.
2004: Raitanen Misa; Worsham Maria J; Lakkala Taina; Carey Thomas E; Van Dyke Daniel L; Grénman Reidar; Klemi Pekka; Rantanen Virpi; Isola Jorma; Grénman Seija
Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry.
Gynecologic oncology 2004;93(1):155-63.
2004: Isola Jorma; Tanner Minna
Chromogenic in situ hybridization in tumor pathology.
Methods in molecular medicine 2004;97():133-44.
2003: Rennstam Karin; Ahlstedt-Soini Minna; Baldetorp Bo; Bendahl Pär-Ola; Borg Ake; Karhu Ritva; Tanner Minna; Tirkkonen Mika; Isola Jorma
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.
Cancer research 2003;63(24):8861-8.
2003: Junttila Teemu T; Laato Matti; Vahlberg Tero; Söderström Karl-Ove; Visakorpi Tapio; Isola Jorma; Elenius Klaus
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5346-57.
2003: Staff Synnöve; Isola Jorma; Tanner Minna
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Cancer research 2003;63(16):4978-83.
2003: Sallinen Satu-Leena; Sallinen Pauli; Ahlstedt-Soini Minna; Haapasalo Hannu; Helin Heikki; Isola Jorma; Karhu Ritva
Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines.
Cancer genetics and cytogenetics 2003;144(1):52-60.
2003: Linja Marika J; Savinainen Kimmo J; Tammela Teuvo L J; Isola Jorma J; Visakorpi Tapio
Expression of ERalpha and ERbeta in prostate cancer.
The Prostate 2003;55(3):180-6.
2003: Johannsson Oskar T; Staff Synnöve; Vallon-Christersson Johan; Kytöla Soili; Gudjonsson Thorarinn; Rennstam Karin; Hedenfalk Ingrid A; Adeyinka Adewale; Kjellén Elisabeth; Wennerberg Johan; Baldetorp Bo; Petersen Ole W; Olsson Håkan; Oredsson Stina; Isola Jorma; Borg Ake
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Laboratory investigation; a journal of technical methods and pathology 2003;83(3):387-96.
2002: Gancberg David; Järvinen Tero; di Leo Angelo; Rouas Ghizlane; Cardoso Fatima; Paesmans Marianne; Verhest Alain; Piccart Martine J; Isola Jorma; Larsimont Denis
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.
Breast cancer research and treatment 2002;74(2):113-20.
2002: Karhu Ritva; Vilpo Leena; Isola Jorma; Knuutila Sakari; Vilpo Juhani
Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation.
Genes, chromosomes & cancer 2002;34(3):345-8.
2002: Kytölä Soili; Nord Brita; Elder Elisabeth Edström; Carling Tobias; Kjellman Magnus; Cedermark Björn; Juhlin Claes; Höög Anders; Isola Jorma; Larsson Catharina
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.
Genes, chromosomes & cancer 2002;34(3):325-32.
2002: Di Leo Angelo; Gancberg David; Larsimont Denis; Tanner Minna; Jarvinen Tero; Rouas Ghizlane; Dolci Stella; Leroy Jean-Yves; Paesmans Marianne; Isola Jorma; Piccart Martine J
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1107-16.
2002: Gancberg D; Di Leo A; Rouas G; Järvinen T; Verhest A; Isola J; Piccart M J; Larsimont D
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.
Journal of clinical pathology 2002;55(4):315-7.
2002: Paunu Niina; Pukkala Eero; Laippala Pekka; Sankila Risto; Isola Jorma; Miettinen Helena; Simola Kalle O J; Helén Pauli; Helin Heikki; Haapasalo Hannu
Cancer incidence in families with multiple glioma patients.
International journal of cancer. Journal international du cancer 2002;97(6):819-22.
2002: Palmu S; Söderström K O; Quazi K; Isola J; Salminen E
Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer.
Anticancer research 2002;22(1A):411-4.
2002: Savinainen Kimmo J; Saramäki Outi R; Linja Marika J; Bratt Ola; Tammela Teuvo L J; Isola Jorma J; Visakorpi Tapio
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
The American journal of pathology 2002;160(1):339-45.
2002: Akervall Jan; Borg Ake; Dictor Michael; Jin Charlotte; Jin Yuesheng; Tanner Minna; Isola Jorma; Mertens Fredrik; Wennerberg Johan
Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
International journal of oncology 2002;20(1):45-52.
2001: Paunu N; Syrjäkoski K; Sankila R; Simola K O; Helén P; Niemelä M; Matikainen M; Isola J; Haapasalo H
Analysis of p53 tumor suppressor gene in families with multiple glioma patients.
Journal of neuro-oncology 2001;55(3):159-65.
2001: Rummukainen J K; Salminen T; Lundin J; Joensuu H; Isola J J
Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples.
Laboratory investigation; a journal of technical methods and pathology 2001;81(11):1545-51.
2001: Staff S; Isola J J; Johannsson O; Borg A; Tanner M M
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
British journal of cancer 2001;85(8):1201-5.
2001: Rummukainen J K; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola J J
Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2001;14(10):1030-5.
2001: Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan C H; Ries F; Gobert P H; Closon-Dejardin M T; Dolci S; Rouas G; Paesmans M; Lobelle J P; Isola J; Piccart M J
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(8):1081-9.
2001: Tanner M; Järvinen P; Isola J
Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Cancer research 2001;61(14):5345-8.
2001: Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen T A; Määttänen L; Stenman U H; Tammela T; Hakama M; Visakorpi T
Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
The Journal of urology 2001;165(5):1569-74.
2001: Rummukainen J; Kytölä S; Karhu R; Farnebo F; Larsson C; Isola J J
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.
Cancer genetics and cytogenetics 2001;126(1):1-7.
2001: Rennstam K; Baldetorp B; Kytölä S; Tanner M; Isola J
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer.
Cancer research 2001;61(3):1214-9.
2001: Pan Y; Lui W O; Nupponen N; Larsson C; Isola J; Visakorpi T; Bergerheim U S; Kytölä S
5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines.
Genes, chromosomes & cancer 2001;30(2):187-95.
2001: Holli K; Saaristo R; Isola J; Joensuu H; Hakama M
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study.
British journal of cancer 2001;84(2):164-9.
2001: Karhu R; Ahlstedt-Soini M; Bittner M; Meltzer P; Trent J M; Isola J J
Chromosome arm-specific multicolor FISH.
Genes, chromosomes & cancer 2001;30(1):105-9.
2000: Miettinen H E; Järvinen T A; Kellner U; Kauraniemi P; Parwaresch R; Rantala I; Kalimo H; Paljärvi L; Isola J; Haapasalo H
High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas.
Neuropathology and applied neurobiology 2000;26(6):504-12.
2000: Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart M J; Isola J
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
The American journal of pathology 2000;157(5):1467-72.
2000: Kauraniemi P; Hedenfalk I; Persson K; Duggan D J; Tanner M; Johannsson O; Olsson H; Trent J M; Isola J; Borg A
MYB oncogene amplification in hereditary BRCA1 breast cancer.
Cancer research 2000;60(19):5323-8.
2000: Staff S; Nupponen N N; Borg A; Isola J J; Tanner M M
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Genes, chromosomes & cancer 2000;28(4):432-42.
2000: Kytölä S; Rummukainen J; Nordgren A; Karhu R; Farnebo F; Isola J; Larsson C
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes, chromosomes & cancer 2000;28(3):308-17.
2000: Nupponen N N; Isola J; Visakorpi T
Mapping the amplification of EIF3S3 in breast and prostate cancer.
Genes, chromosomes & cancer 2000;28(2):203-10.
2000: Tanner M M; Grenman S; Koul A; Johannsson O; Meltzer P; Pejovic T; Borg A; Isola J J
Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1833-9.
2000: Borg A; Isola J; Chen J; Rubio C; Johansson U; Werelius B; Lindblom A
Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.
International journal of cancer. Journal international du cancer 2000;85(6):796-800.
2000: Järvinen T A; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
The American journal of pathology 2000;156(3):839-47.
2000: Järvinen T A; Pelto-Huikko M; Holli K; Isola J
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.
The American journal of pathology 2000;156(1):29-35.
1999: Isola J; Chu L; DeVries S; Matsumura K; Chew K; Ljung B M; Waldman F M
Genetic alterations in ERBB2-amplified breast carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4140-5.
1999: Järvinen T A; Tanner M; Bärlund M; Borg A; Isola J
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Genes, chromosomes & cancer 1999;26(2):142-50.
1999: Nupponen N N; Porkka K; Kakkola L; Tanner M; Persson K; Borg A; Isola J; Visakorpi T
Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.
The American journal of pathology 1999;154(6):1777-83.
1999: Persson K; Pandis N; Mertens F; Borg A; Baldetorp B; Killander D; Isola J
Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization.
Genes, chromosomes & cancer 1999;25(2):115-22.
1999: Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Journal of neuro-oncology 1999;41(3):205-11.
1999: Karhu R; Rummukainen J; Lörch T; Isola J
Four-color CGH: a new method for quality control of comparative genomic hybridization.
Genes, chromosomes & cancer 1999;24(2):112-8.
1999: Pan Y; Kytölä S; Farnebo F; Wang N; Lui W O; Nupponen N; Isola J; Visakorpi T; Bergerheim U S; Larsson C
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenetics and cell genetics 1999;87(3-4):225-32.
1998: Holli K; Isola J; Cuzick J
Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3115-20.
1998: Holli K; Saaristo R; Isola J; Hyöty M; Hakama M
Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study.
British journal of cancer 1998;78(4):542-5.
1998: Tanner M M; Karhu R A; Nupponen N N; Borg A; Baldetorp B; Pejovic T; Fernö M; Killander D; Isola J J
Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene.
The American journal of pathology 1998;153(1):191-9.
1998: Järvinen T A; Holli K; Kuukasjärvi T; Isola J J
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
British journal of cancer 1998;77(12):2267-73.
1998: Tirkkonen M; Tanner M; Karhu R; Kallioniemi A; Isola J; Kallioniemi O P
Molecular cytogenetics of primary breast cancer by CGH.
Genes, chromosomes & cancer 1998;21(3):177-84.
1997: Sallinen S L; Sallinen P; Haapasalo H; Kononen J; Karhu R; Helén P; Isola J
Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas.
The American journal of pathology 1997;151(6):1799-807.
1997: Koivisto P; Visakorpi T; Rantala I; Isola J
Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer.
The Journal of pathology 1997;183(1):51-6.
1997: Karhu R; Siitonen S; Tanner M; Keinänen M; Mäkipernaa A; Lehtinen M; Vilpo J A; Isola J
Genetic aberrations in pediatric acute lymphoblastic leukemia by comparative genomic hybridization.
Cancer genetics and cytogenetics 1997;95(2):123-9.
1997: Kuukasjärvi T; Karhu R; Tanner M; Kähkönen M; Schäffer A; Nupponen N; Pennanen S; Kallioniemi A; Kallioniemi O P; Isola J
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.
Cancer research 1997;57(8):1597-604.
1997: Tirkkonen M; Johannsson O; Agnarsson B A; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir R B; Borg A; Kallioniemi O P
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Cancer research 1997;57(7):1222-7.
1997: Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi O P; Isola J
Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
The American journal of pathology 1997;150(4):1465-71.
1997: Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Visakorpi T; Isola J
Optimizing DOP-PCR for universal amplification of small DNA samples in comparative genomic hybridization.
Genes, chromosomes & cancer 1997;18(2):94-101.
1997: Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi O P
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Cancer research 1997;57(2):314-9.
1997: Palmberg C; Koivisto P; Hyytinen E; Isola J; Visakorpi T; Kallioniemi O P; Tammela T
Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.
European urology 1997;31(2):216-9.
1996: Tirkkonen M; Karhu R; Kallioniemi O; Isola J
Evaluation of camera requirements for comparative genomic hybridization.
Cytometry 1996;25(4):394-8.
1996: Nikkari S T; Höyhtyä M; Isola J; Nikkari T
Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis.
The American journal of pathology 1996;149(5):1427-33.
1996: Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2584-9.
1996: Tanner M M; Tirkkonen M; Kallioniemi A; Isola J; Kuukasjärvi T; Collins C; Kowbel D; Guan X Y; Trent J; Gray J W; Meltzer P; Kallioniemi O P
Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer.
Cancer research 1996;56(15):3441-5.
1996: Kainu T; Kononen J; Johansson O; Olsson H; Borg A; Isola J
Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization.
Cancer research 1996;56(13):2912-5.
1996: Järvinen T A; Kononen J; Pelto-Huikko M; Isola J
Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.
The American journal of pathology 1996;148(6):2073-82.
1996: Haapasalo H; Hyytinen E; Sallinen P; Helin H; Kallioniemi O P; Isola J
c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization.
British journal of cancer 1996;73(5):620-3.
1995: Tanner M M; Tirkkonen M; Kallioniemi A; Holli K; Collins C; Kowbel D; Gray J W; Kallioniemi O P; Isola J
Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1455-61.
1995: Koivisto P; Hyytinen E; Palmberg C; Tammela T; Visakorpi T; Isola J; Kallioniemi O P
Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.
The American journal of pathology 1995;147(6):1608-14.
1995: Visakorpi T; Hyytinen E; Koivisto P; Tanner M; Keinänen R; Palmberg C; Palotie A; Tammela T; Isola J; Kallioniemi O P
In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
Nature genetics 1995;9(4):401-6.
1995: Holli K; Isola J; Hakama M
Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy.
British journal of cancer 1995;71(1):124-7.
1995: Hakama M; Holli K; Isola J; Kallioniemi O P; Kärkkäinen A; Visakorpi T; Pukkala E; Saarenmaa I; Geiger U; Ikkala J
Aggressiveness of screen-detected breast cancers.
Lancet 1995;345(8944):221-4.
1994: Isola J; DeVries S; Chu L; Ghazvini S; Waldman F
Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples.
The American journal of pathology 1994;145(6):1301-8.
1994: Visakorpi T; Hyytinen E; Kallioniemi A; Isola J; Kallioniemi O P
Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization.
The American journal of pathology 1994;145(3):624-30.
1994: Sallinen P; Haapasalo H; Kerttula T; Rantala I; Kalimo H; Collan Y; Isola J; Helin H
Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1994;16(4):261-8.
1994: Kallioniemi O P; Kallioniemi A; Piper J; Isola J; Waldman F M; Gray J W; Pinkel D
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors.
Genes, chromosomes & cancer 1994;10(4):231-43.
1994: Wichmann L; Isola J; Tuohimaa P
Prognostic variables in predicting pregnancy. A prospective follow up study of 907 couples with an infertility problem.
Human reproduction (Oxford, England) 1994;9(6):1102-8.
1994: Gray J W; Collins C; Henderson I C; Isola J; Kallioniemi A; Kallioniemi O P; Nakamura H; Pinkel D; Stokke T; Tanner M
Molecular cytogenetics of human breast cancer.
Cold Spring Harbor symposia on quantitative biology 1994;59():645-52.
1993: Haapasalo H; Isola J; Sallinen P; Kalimo H; Helin H; Rantala I
Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.
The American journal of pathology 1993;142(5):1347-51.
1993: Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi O P
Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):36-43.
1993: Visakorpi T; Kallioniemi O P; Koivula T; Isola J
New prognostic factors in prostatic carcinoma.
European urology 1993;24(4):438-49.
1992: Isola J; Visakorpi T; Holli K; Kallioniemi O P
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Journal of the National Cancer Institute 1992;84(14):1109-14.
1992: Visakorpi T; Kallioniemi O P; Heikkinen A; Koivula T; Isola J
Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.
Journal of the National Cancer Institute 1992;84(11):883-7.
1991: Kallioniemi O P; Visakorpi T; Holli K; Heikkinen A; Isola J; Koivula T
Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing.
Cytometry 1991;12(5):413-21.
1991: Kallioniemi O P; Holli K; Visakorpi T; Koivula T; Helin H; Isola J
[New studies on breast cancer to predict disease outcome and clinical use of these new tests]
Duodecim; lääketieteellinen aikakauskirja 1991;107(11):907-16.
1990: Isola J; Kallioniemi O P; Korte J M; Wahlström T; Aine R; Helle M; Helin H
Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
The Journal of pathology 1990;162(4):295-301.
1990: Helin H; Isola J; Helle M; Koivula T
Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
British journal of cancer 1990;62(1):109-12.
1989: Tuohimaa P; Joensuu T; Isola J; Keinänen R; Kunnas T; Niemelä A; Pekki A; Wallén M; Ylikomi T; Kulomaa M
Development of progestin-specific response in the chicken oviduct.
The International journal of developmental biology 1989;33(1):125-34.
1988: Vilja P; Wichmann L; Isola J; Tuohimaa P
Monoclonal-antibody-based noncompetitive avidin-biotin assay for lutropin in urine.
Clinical chemistry 1988;34(8):1585-90.
1988: Helle M; Helin H; Isola J
[Determination of steroid receptors in breast cancer by immunohisto- chemical technics]
Duodecim; lääketieteellinen aikakauskirja 1988;104(20):1605-13.
1987: Isola J; Pelto-Huikko M; Ylikomi T; Tuohimaa P
Immunoelectron microscopic localization of progesterone receptor in the chick oviduct.
Journal of steroid biochemistry 1987;26(1):19-23.
1986: Isola J; Ylikomi T; Tuohimaa P
Nuclear origin of progesterone receptor of the chick oviduct cytosol. An immunoelectron microscopic study.
Histochemistry 1986;86(1):53-8.
1984: Ylikomi T; Isola J; Ratia J; Vähä-Tahlo T; Tuohimaa P
Augmentation of progesterone receptor concentration by progesterone and estrogen treatments in the chick oviduct.
Journal of steroid biochemistry 1984;20(1):445-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jorma Isola

Research Profile (preview)

Disorders

Procedures

Physiology

Chemicals & Drugs

Phenomena

Genes & Molecular Sequences

Anatomy

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jorma Isola (preview)

All Publications